Tremelimumab

Generic Name: Tremelimumab

Brand Names: Imjudo, Tremelimumab AstraZeneca

Drug Type: Biotech

Chemical Formula: -

CAS Number: 745013-59-6

Unique Ingredient Identifier: QEN1X95CIX

Background: Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...

Indication: Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...

Associated Conditions: Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)

Associated Therapies: -

Clinical Trials

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2017-04-26

Last Posted Date: 2017-12-06

Lead Sponsor: Columbia University

Registration Number: NCT03130764

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: durvalumab
Drug: tremelimumab
Radiation: Radiotherapy (RT)
Procedure: ablation

First Posted Date: 2017-04-20

Last Posted Date: 2022-07-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT03122509

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Phase 1

Completed

Conditions: Metastatic Anaplastic Thyroid Cancer

Interventions: Drug: durvalumab
Drug: tremelimumab
Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2017-04-20

Last Posted Date: 2022-06-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT03122496

Locations: 🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering @ Rockville, Rockville Centre, New York, United States

and more 5 locations

Synergism of Immunomodulation and Tumor Ablation

Phase 2

Completed

Conditions: Colorectal Cancer
Liver Metastases

Interventions: Drug: Durvalumab (MEDI4736)
Drug: Tremelimumab
Radiation: Sterotactic body radiation therapy (SBRT)
Other: Radiofrequency ablation (RFA)

First Posted Date: 2017-04-05

Last Posted Date: 2022-05-31

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 22

Registration Number: NCT03101475

Locations: 🇳🇱
Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
🇨🇭
Inselspital, Bern, Switzerland
🇫🇷
Institut Bergonie, Bordeaux, France

and more 7 locations

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Phase 2

Completed

Conditions: Neuroendocrine Tumors
Neuroendocrine Neoplasm of Lung

Interventions: Drug: Tremelimumab
Drug: Durvalumab

First Posted Date: 2017-03-29

Last Posted Date: 2023-02-23

Lead Sponsor: Grupo Espanol de Tumores Neuroendocrinos

Target Recruit Count: 123

Registration Number: NCT03095274

Locations: 🇪🇸
Instituto Catalán de Oncología Badalona, Badalona, Barcelona, Spain
🇪🇸
Hospital Duran i Reynals/ICO L'Hospitalet, Barcelona, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 16 locations

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase 1

Completed

Conditions: Extensive-stage Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Tremelimumab
Drug: SGI-110

First Posted Date: 2017-03-21

Last Posted Date: 2018-12-10

Lead Sponsor: Catherine Shu

Target Recruit Count: 2

Registration Number: NCT03085849

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

Phase 2

Terminated

Conditions: Germ Cell Tumor

Interventions: Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2017-03-16

Last Posted Date: 2021-05-14

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 36

Registration Number: NCT03081923

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2

Suspended

Conditions: Mesothelioma

Interventions: Drug: Tremelimumab
Drug: Durvalumab

First Posted Date: 2017-03-09

Last Posted Date: 2024-01-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT03075527

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Phase 2

Active, not recruiting

Conditions: Lung Cancer Metastatic

Interventions: Drug: Durvalumab
Drug: Tremelimumab
Drug: Platinum-Based Drug

First Posted Date: 2017-02-17

Last Posted Date: 2024-04-23

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 301

Registration Number: NCT03057106

Locations: 🇨🇦
Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇦🇺
Coffs Habour Health Campus - NCCI, Coffs Harbour, New South Wales, Australia

and more 46 locations

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Phase 2

Active, not recruiting

Conditions: Biliary Tract Neoplasms

Interventions: Drug: Durvalumab
Drug: Tremelimumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2017-02-08

Last Posted Date: 2024-04-19

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 31

Registration Number: NCT03046862

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy